ArriVent Announces Program Update from the Phase 3 FURVENT Trial of Firmonertinib in First-Line EGFR Exon 20 Insertion Mutant NSCLC
Key Highlights
- ➤FURVENT Phase 3 failed its primary BICR-assessed PFS endpoint
- ➤Firmonertinib 240mg median BICR PFS reached 11.0 months versus 9.5 months control
- ➤Investigator-assessed median PFS reached 11.1 months versus 7.1 months control
- ➤Confirmed BICR objective response rate reached 60% at 240mg versus 33% control
- ➤FURVENT safety profile showed no new safety signals versus previous studies
Expert Statements
Bing Yao, Chairman and Chief Executive Officer of ArriVent
“These disappointing results are not what we hoped for, particularly for the patients with EGFR exon 20 insertion-mutant NSCLC who urgently need more effective treatment options. While the safety profile observed with firmonertinib was consistent with previous clinical studies, FURVENT did not show a meaningful improvement in PFS over chemotherapy by BICR in this study. We are deeply grateful to the patients, investigators and clinical teams who made this program possible and are evaluating the full FURVENT dataset as we determine the most appropriate development path for firmonertinib.”
NEWTOWN SQUARE, Pa., Oct. 06, 2026 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced that the FURVENT (NCT05607550) Phase 3 trial evaluating firmonertinib monotherapy in patients with previously untreated, locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) harboring EGFR exon 20 insertion mutations did not meet its primary endpoint of progression free survival (PFS) by blinded independent central review (BICR). Clinical benefit was observed with secondary endpoints such as PFS by investigator’s assessment and confirmed objective response rate by BICR. Although not yet mature, a trend toward an improvement in overall survival was also observed. The safety profile observed in FURVENT was consistent with previous clinical studies of firmonertinib, with no new safety signals identified.
Get started
Create a free account to read the full story.